@article{bdc28f144197497d835271b5075ef370,
title = "Response to Comment on Vistisen et al. A validated prediction model for endstage kidney disease in type 1 diabetes. Diabetes care 2021;44:901–907",
author = "Dorte Vistisen and Andersen, \{Gregers S.\} and Adam Hulman and McGurnaghan, \{Stuart J.\} and Colhoun, \{Helen M.\} and Henriksen, \{Jan E.\} and Thomsen, \{Reimar W.\} and Frederik Persson and Peter Rossing and J{\o}rgensen, \{Marit E.\}",
note = "Funding Information: served as a consultant for AstraZeneca, As-tellas, Bayer, Boehringer Ingelheim, Gilead, Merck, Mundipharma, Vifor, Sanofi, and Novo Nordisk A/S (all honoraria to his institution) and received research grants from AstraZeneca and Novo Nordisk A/S. M.E.J. has received research grants from AstraZe-neca, Amgen, Sanofi, and Boehringer Ingel-heim (investigator-initiated research). M.E.J. also owns shares in Novo Nordisk A/S. No other potential conflicts of interest relevant to this article were reported. Funding Information: Funding. The Steno Diabetes Centers (Aarhus and Copenhagen) are partially funded by an unrestricted donation from the Novo Nordisk Foundation. Duality of Interest. D.V. and G.S.A. own shares in Novo Nordisk A/S. F.P. reports having received research grants from AstraZene-ca and lecture fees from AstraZeneca, MSD, Janssen, Eli Lilly, Boehringer Ingelheim, Novo Nordisk A/S, and Novartis as well as being a consultant/advisory board member for Astra-Zeneca, Bayer, Amgen, and MSD. P.R. has",
year = "2021",
month = jun,
doi = "10.2337/dci21-0010",
language = "English",
volume = "44",
pages = "e140--e141",
journal = "Diabetes Care",
issn = "0149-5992",
publisher = "American Diabetes Association Inc.",
number = "6",
}